Conference Coverage: AAAAI 2014
Thomas A. Fleisher, MD, senior investigator at the National Institutes of Health Clinical Center, discussed promising improvements in genomic screening on March 1, 2014, during a special session on pediatric issues at the American Academy of Allergy, Asthma & Immunology, held in San Diego, California.
Fleisher said that genomic screening is leading to earlier and better treatments of immunologic disorders, including those caught early in newborns as a result of screening done at birth.
Fleisher discussed an assay of T-cell receptor excision circles (TREC), based on work in California, which initiated newborn screening for severe combined immunodeficiency (SCID) in 2010.
Fleisher said the results, published in July 2013, offer a glimpse of what could happen as this kind of screening becomes widely available.1 Of nearly 1 million infants screened, 50 had significant T-cell lymphopenia; 15 required hematopoietic cell or thymus transplantation or gene therapy.
At the time of the study’s publication, the survival rate of this group was 93%. What’s more, the TREC test specificity was excellent, only 0.08% of infants required a second test, with 0.16% requiring lymphocyte phenotyping by using flow cytometry.1 Having this information guides families and physicians, and it saves lives, he said. Infants who test positive for SCID, for example, do not receive the vaccine for rotavirus, based on a June 2011 advisory from the Centers for Disease Control and Prevention. Even before the announcement, Merck and GlaxoSmithKline, the makers of the RotaTeq and Rotarix, respectively, updated their labeling with approval from the US Food and Drug Administration to reflect the contraindication.2
“This shows that screening newborns is working,” Fleisher said of the California results. “Eighteen states now have routine screening for T-cell immunodeficiency,” which covers more than 50% of the infants born in the United States. As time goes on and data accumulate, he said, “We will understand more about the TREC results.”
Genomics will be “front and center” over the next 10 years, he said. Fleisher was among the speakers of the day who said a $1000 price tag to map an individual genome was “not far away.”
The use of genomics for personalized—and especially preventative—medicine will only increase. “There are 250 genes associated with immunology disorders and that number will grow,”
Fleisher said. For all the excitement, however, he cautioned that there are ethical concerns about storage and access of the information that must be addressed, in addition to the question of how much information is extracted about a newborn who has no say in how much information is gleaned from his or her genome.
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been falling. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More